Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACQUISITION (Tables)

6 Months Ended

Mar. 31, 2019

The pro forma adjustments are based upon available information and certain assumptions that the Company believes are reasonable.

Pro Forma	Three Months Ended March 31, 2018			Six Months Ended March 31, 2018
Revenues	$	459,900		$	727,100
Net income (loss)		(2,659,600	)		(5,605,300	)
Basic and diluted loss per share:	$	(0.61	)	$	(1.29	)

Outstanding at weighted average shares outstanding		4,362,564			4,347,745